Key result
This review summarizes clinical trials addressing the primary prevention and secondary prophylaxis of venous thromboembolism in cancer patients using traditional and novel anticoagulants.
Why the study?
Do anticoagulants prevent or treat venous thromboembolism in patients with cancer?
Population
Patients with cancer at risk for or with venous thromboembolism (VTE)
Design
Review
Authors
Loading...
May inform VTE management in cancer; leaves open optimal novel anticoagulant strategies pending further trials.
Do anticoagulants prevent or treat venous thromboembolism in patients with cancer?
This review summarizes current evidence and limitations of traditional anticoagulants for VTE in cancer patients, highlighting the potential role of novel anticoagulants.
Agnes Lee (2005) conducted a review in Venous thromboembolism in cancer. Anticoagulants (low-molecular-weight heparins, vitamin K antagonists) was evaluated. This review summarizes clinical trials addressing the primary prevention and secondary prophylaxis of venous thromboembolism in cancer patients using traditional and novel anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: